DOCSLIB.ORG

The Role of Phospholipase C in Gabaergic Inhibition and Its Relevance to Epilepsy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Role of Phospholipase C in Gabaergic Inhibition and Its Relevance to Epilepsy International Journal of Molecular Sciences Review The Role of Phospholipase C in GABAergic Inhibition and Its Relevance to Epilepsy Hye Yun Kim 1, Pann-Ghill Suh 1,2 and Jae-Ick Kim 1,* 1 Department of Biological Sciences, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Korea; [email protected] (H.Y.K.); [email protected] (P.-G.S.) 2 Korea Brain Research Institute (KBRI), Daegu 41062, Korea * Correspondence: [email protected]; Tel.: +82-52-217-2458 Abstract: Epilepsy is characterized by recurrent seizures due to abnormal hyperexcitation of neurons. Recent studies have suggested that the imbalance of excitation and inhibition (E/I) in the central nervous system is closely implicated in the etiology of epilepsy. In the brain, GABA is a major inhibitory neurotransmitter and plays a pivotal role in maintaining E/I balance. As such, altered GABAergic inhibition can lead to severe E/I imbalance, consequently resulting in excessive and hypersynchronous neuronal activity as in epilepsy. Phospholipase C (PLC) is a key enzyme in the intracellular signaling pathway and regulates various neuronal functions including neuronal development, synaptic transmission, and plasticity in the brain. Accumulating evidence suggests that neuronal PLC is critically involved in multiple aspects of GABAergic functions. Therefore, a better understanding of mechanisms by which neuronal PLC regulates GABAergic inhibition is necessary for revealing an unrecognized linkage between PLC and epilepsy and developing more effective treatments for epilepsy. Here we review the function of PLC in GABAergic inhibition in the brain and discuss a pathophysiological relationship between PLC and epilepsy. Citation: Kim, H.Y.; Suh, P.-G.; Kim, J.-I. The Role of Phospholipase C in Keywords: Phospholipase C (PLC); γ-aminobutyric acid (GABA); excitatory/inhibitory balance (E/I GABAergic Inhibition and Its balance); GABAergic inhibition; epilepsy Relevance to Epilepsy. Int. J. Mol. Sci. 2021, 22, 3149. https://doi.org/ 10.3390/ijms22063149 1. Introduction Academic Editor: Epilepsy, one of the most common neurological disorders, is characterized by re- Giangennaro Coppola peated spontaneous seizures with abnormal hyperexcitation and synchronous discharge of neurons [1]. Approximately 60 million people worldwide suffer from epilepsy with Received: 29 November 2020 cognitive and psychiatric comorbidities [2,3]. Although several biological factors have Accepted: 17 March 2021 Published: 19 March 2021 been identified as an etiology of epilepsy, including genetic mutation, brain injury, tumor, and aging, the precise cause of epilepsy in most cases is still unknown [4,5]. One of the hy- Publisher’s Note: MDPI stays neutral potheses explaining the pathophysiological mechanism of epilepsy is that the disruption of with regard to jurisdictional claims in excitation and inhibition balance (E/I balance) could generally lead to abnormal excitability published maps and institutional affil- of neurons [6–8]. In the brain, neurons receive numerous excitatory and inhibitory synaptic iations. inputs and once the synaptic potentials in dendrites and soma are integrated together, neurons produce axon potentials with various shapes, rates, and patterns of firing [9]. E/I balance either by increasing excitation or decreasing inhibition is associated with the hyperexcitation of neurons, which can cause epileptic seizures [7,10,11]. γ-aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the brain and Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. using GABA, GABAergic inhibitory neurons primarily regulate the excitability of neurons. This article is an open access article GABAergic neurons produce GABA from glutamate using glutamic acid decarboxylase distributed under the terms and (GAD) and this synthesized GABA is packaged into synaptic vesicles at synaptic terminals conditions of the Creative Commons through vesicular GABA transporters (VGATs). Synaptically released GABA binds to both Attribution (CC BY) license (https:// presynaptic and postsynaptic GABA receptors (GABAA and GABAB) and suppresses the creativecommons.org/licenses/by/ excitation of presynaptic terminals and postsynaptic neurons. In addition, the uptake 4.0/). of released GABA at GABAergic synapses is mediated by GABA transporters (GATs). Int. J. Mol. Sci. 2021, 22, 3149. https://doi.org/10.3390/ijms22063149 https://www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 2 of 17 Int. J. Mol. Sci. 2021, 22, 3149 2 of 17 the uptake of released GABA at GABAergic synapses is mediated by GABA transporters Molecular(GATs). Molecular and cellular and abnormalitiescellular abnormalities of GABA of synthesis,GABA synthesis, release, release, uptake, uptake, and GABA and receptor-mediatedGABA receptor-mediated signaling signaling can alter can E/I alter balance E/I balance in neurons in neurons and and the the dysfunctions dysfunctions of anyof any of of these these processes processes may may be be implicated implicated in in neurological neurological disordersdisorders includingincluding epilepsy, schizophrenia, and autism [[1212–1414]].. As a matter of fact,fact, thethe therapeutictherapeutic rationalerationale ofof thethe majority ofof currentcurrent antiepilepticantiepileptic drugsdrugs (AEDs)(AEDs) isis toto restorerestore alteredaltered E/I E/I balance by elevating thethe levellevel ofof GABAGABA atat synapsessynapses and and potentiating potentiating the the functions functions of of GABA GABA receptors. receptors. Hence, Hence, a bettera better understanding understanding of of the the underlying underlying molecular molecular mechanisms mechanisms thatthat regulateregulate GABAergicGABAergic inhibitioninhibition inin thethe brain brain will will be be crucial crucial to to identify identify new new drug drug targets, targets, as wellas well as toas increase to increase the efficacythe efficacy and and minimize minimize the sidethe side effects effects of antiepileptic of antiepileptic drugs. drugs. Phospholipase CC (PLC)(PLC) is is an an essential essential enzyme enzyme in intracellularin intracellular signal signal transduction transduction cas- cadescascades (Figure (Figure1). PLC 1). PLC hydrolyzes hydrolyzes phosphatidylinositol phosphatidylinositol 4,5-bisphosphate 4,5-bisphosphate (PIP 2(PIP), generating2), gener- secondaryating seconda signalry signal transducers transducers including including inositol inositol 1,4,5-triphosphate 1,4,5-triphosphate (IP3) and (IP diacylglycerol3) and diacyl- (DAG).glycerol IP (DAG).3 increases IP3 increases intracellular intracellular calcium calcium level by level binding by binding to IP3 receptors to IP3 receptors in the endo-in the plasmicendoplasmic reticulum reticulum and DAGand DAG activates activates protein protein kinase kinase C (PKC)-related C (PKC)-related signaling signaling cascades. cas- Throughoutcades. Throughout the body, the PLC body, is PLC associated is associated with key with cellular key cellular processes processes such as such proliferation, as prolif- differentiation,eration, differentiation, migration, migration, and survival and [survival15–18]. There [15–18] are. There in total are 13 in mammalian total 13 mammalian isozymes ofisozymes PLC including of PLC includingβ (1–4), γ β(1, (1 2),–4),δ γ(1, (1, 3, 2), 4), δ" (1,, ζ ,3, and 4), ε,η (1,ζ, and 2), whichη (1, 2), are wh classifiedich are classified accord- ingaccording to their to distinct their distinct domain domain structures structures and biochemical and biochemical properties. properties. Each PLC Each isozyme PLC iso- is differentiallyzyme is differentially expressed expressed among tissues among and tissues regulates and regulates the complex the complex cellular functionscellular func- in a tissue-dependenttions in a tissue-dependent manner. Among manner. these Among PLC isozymes,these PLC PLCisozymes,β and PLCPLCβγ areand major PLCγ PLC are enzymesmajor PLC abundantly enzymes abundantly expressed inexpressed the brain in and the playbrain diverse and play roles diverse in neuronal roles in functions. neuronal Infunctions. this review In this article, review we summarizearticle, we summarize the molecular the and molecular cellular and mechanisms cellular mechanisms of GABAergic of inhibitionGABAergic on inhibition the regulation on the of regulation E/I balance. of E/I Then balance. we particularly Then we particularly focus on the focus role of on PLC the inrole GABAergic of PLC in inhibition.GABAergic Finally, inhibition. we discuss Finally, the we potential discuss relationship the potential between relationship PLC and be- epilepsy.tween PLC and epilepsy. FigureFigure 1.1. The principalprincipal PLCPLC signalingsignaling cascadescascades andand functionsfunctions inin thethe brain.brain. External ligandsligands such asas neurotransmitters andand neurotrophic factors bind to and activate the upstream transmembrane receptors of PLC. PLCβ is activated by Gαq and neurotrophic factors bind to and activate the upstream transmembrane receptors of PLC. PLCβ is activated by Gαq and Gβγ subunits of G protein-coupled receptors (GPCRs), whereas the activation of PLCγ is triggered by the phosphorylation Gβγ subunits of G protein-coupled receptors (GPCRs), whereas the activation of PLCγ is triggered by the phosphorylation of receptor tyrosine kinases (RTKs). Activation of PLC hydrolyzes phospholipid PIP2 into IP3 and DAG and these second ofmessengers receptor tyrosine mediate kinases diverse (RTKs). neuronal Activation functions.
Load more

Recommended publications
  • WELLBUTRIN SR Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION psychosis, hallucinations, paranoia, delusions, homicidal ideation, These highlights do not include all the information needed to use aggression, hostility, agitation, anxiety, and panic, as well as suicidal WELLBUTRIN SR safely and effectively. See full prescribing ideation, suicide attempt, and completed suicide. Observe patients information for WELLBUTRIN SR. attempting to quit smoking with bupropion for the occurrence of such symptoms and instruct them to discontinue bupropion and contact a WELLBUTRIN SR (bupropion hydrochloride) sustained-release tablets, healthcare provider if they experience such adverse events. (5.2) for oral use • Initial U.S. Approval: 1985 Seizure risk: The risk is dose-related. Can minimize risk by gradually increasing the dose and limiting daily dose to 400 mg. Discontinue if WARNING: SUICIDAL THOUGHTS AND BEHAVIORS seizure occurs. (4, 5.3, 7.3) See full prescribing information for complete boxed warning. • Hypertension: WELLBUTRIN SR can increase blood pressure. Monitor blood pressure before initiating treatment and periodically during • Increased risk of suicidal thinking and behavior in children, treatment. (5.4) adolescents and young adults taking antidepressants. (5.1) • Activation of mania/hypomania: Screen patients for bipolar disorder and • Monitor for worsening and emergence of suicidal thoughts and monitor for these symptoms. (5.5) behaviors. (5.1) • Psychosis and other neuropsychiatric reactions: Instruct patients to contact a healthcare professional if such reactions occur. (5.6) --------------------------- INDICATIONS AND USAGE ---------------------------- • Angle-closure glaucoma: Angle-closure glaucoma has occurred in WELLBUTRIN SR is an aminoketone antidepressant, indicated for the patients with untreated anatomically narrow angles treated with treatment of major depressive disorder (MDD). (1) antidepressants.
    [Show full text]
  • Silencing of Phosphoinositide-Specific
    ANTICANCER RESEARCH 34: 4069-4076 (2014) Silencing of Phosphoinositide-specific Phospholipase C ε Remodulates the Expression of the Phosphoinositide Signal Transduction Pathway in Human Osteosarcoma Cell Lines VINCENZA RITA LO VASCO1, MARTINA LEOPIZZI2, DANIELA STOPPOLONI3 and CARLO DELLA ROCCA2 Departments of 1Sense Organs , 2Medicine and Surgery Sciences and Biotechnologies and 3Biochemistry Sciences “A. Rossi Fanelli”, Sapienza University, Rome, Italy Abstract. Background: Ezrin, a member of the signal transduction pathway (5). The reduction of PIP2 ezrin–radixin–moesin family, is involved in the metastatic induces ezrin dissociation from the plasma membrane (6). spread of osteosarcoma. Ezrin binds phosphatydil inositol-4,5- The levels of PIP2 are regulated by the PI-specific bisphosphate (PIP2), a crucial molecule of the phospholipase C (PI-PLC) family (7), constituting thirteen phosphoinositide signal transduction pathway. PIP2 levels are enzymes divided into six sub-families on the basis of amino regulated by phosphoinositide-specific phospholipase C (PI- acid sequence, domain structure, mechanism of recruitment PLC) enzymes. PI-PLCε isoform, a well-characterized direct and tissue distribution (7-15). PI-PLCε, a direct effector of effector of rat sarcoma (RAS), is at a unique convergence RAS (14-15), might be the point of convergence for the point for the broad range of signaling pathways that promote broad range of signalling pathways that promote the RAS GTPase-mediated signalling. Materials and Methods. By RASGTPase-mediated signalling (16). using molecular biology methods and microscopic analyses, In previous studies, we suggested a relationship between we analyzed the expression of ezrin and PLC genes after PI-PLC expression and ezrin (17-18).
    [Show full text]
  • Molecular Dissection of G-Protein Coupled Receptor Signaling and Oligomerization
    MOLECULAR DISSECTION OF G-PROTEIN COUPLED RECEPTOR SIGNALING AND OLIGOMERIZATION BY MICHAEL RIZZO A Dissertation Submitted to the Graduate Faculty of WAKE FOREST UNIVERSITY GRADUATE SCHOOL OF ARTS AND SCIENCES in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY Biology December, 2019 Winston-Salem, North Carolina Approved By: Erik C. Johnson, Ph.D. Advisor Wayne E. Pratt, Ph.D. Chair Pat C. Lord, Ph.D. Gloria K. Muday, Ph.D. Ke Zhang, Ph.D. ACKNOWLEDGEMENTS I would first like to thank my advisor, Dr. Erik Johnson, for his support, expertise, and leadership during my time in his lab. Without him, the work herein would not be possible. I would also like to thank the members of my committee, Dr. Gloria Muday, Dr. Ke Zhang, Dr. Wayne Pratt, and Dr. Pat Lord, for their guidance and advice that helped improve the quality of the research presented here. I would also like to thank members of the Johnson lab, both past and present, for being valuable colleagues and friends. I would especially like to thank Dr. Jason Braco, Dr. Jon Fisher, Dr. Jake Saunders, and Becky Perry, all of whom spent a great deal of time offering me advice, proofreading grants and manuscripts, and overall supporting me through the ups and downs of the research process. Finally, I would like to thank my family, both for instilling in me a passion for knowledge and education, and for their continued support. In particular, I would like to thank my wife Emerald – I am forever indebted to you for your support throughout this process, and I will never forget the sacrifices you made to help me get to where I am today.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Inhibitory Role for GABA in Autoimmune Inflammation
    Inhibitory role for GABA in autoimmune inflammation Roopa Bhata,1, Robert Axtella, Ananya Mitrab, Melissa Mirandaa, Christopher Locka, Richard W. Tsienb, and Lawrence Steinmana aDepartment of Neurology and Neurological Sciences and bDepartment of Molecular and Cellular Physiology, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA 94305 Contributed by Richard W. Tsien, December 31, 2009 (sent for review November 30, 2009) GABA, the principal inhibitory neurotransmitter in the adult brain, serum (13). Because actions of exogenous GABA on inflammation has a parallel inhibitory role in the immune system. We demon- and of endogenous GABA on phasic synaptic inhibition both strate that immune cells synthesize GABA and have the machinery occur at millimolar concentrations (5, 8, 9), we hypothesized that for GABA catabolism. Antigen-presenting cells (APCs) express local mechanisms may also operate in the peripheral immune functional GABA receptors and respond electrophysiologically to system to enhance GABA levels near the inflammatory focus. We GABA. Thus, the immune system harbors all of the necessary first asked whether immune cells have synthetic machinery to constituents for GABA signaling, and GABA itself may function as produce GABA by Western blotting for GAD, the principal syn- a paracrine or autocrine factor. These observations led us to ask thetic enzyme. We found significant amounts of a 65-kDa subtype fl further whether manipulation of the GABA pathway in uences an of GAD (GAD-65) in dendritic cells (DCs) and lower levels in animal model of multiple sclerosis, experimental autoimmune macrophages (Fig. 1A). GAD-65 increased when these cells were encephalomyelitis (EAE). Increasing GABAergic activity amelio- stimulated (Fig.
    [Show full text]
  • A 3-Fold Kernel Approach for Characterizing Late Onset Alzheimer’S Disease
    bioRxiv preprint doi: https://doi.org/10.1101/397760; this version posted August 22, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. A 3-fold kernel approach for characterizing Late Onset Alzheimer’s Disease Margherita Squillarioa,*, Federico Tomasia, Veronica Tozzoa, Annalisa Barlaa and Daniela Ubertib “for the Alzheimer’s Disease Neuroimaging Initiative**” aDIBRIS, University of Genoa, Via Dodecaneso 35, I-16146 Genova, Italy. E-mail address: {squillario, federico.tomasi, veronica.tozzo}@dibris.unige.it, [email protected] bDepartment of Molecular and Translational Medicine, University of Brescia, Viale Europa 11, 25123, Brescia, Italy. E-mail address: [email protected] * Corresponding author and Lead Contact. Tel: +39-010-353-6707; Fax: +39-010-353- 6699. ** Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp- content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf 1 bioRxiv preprint doi: https://doi.org/10.1101/397760; this version posted August 22, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Alterations in Behavioral Responses to a Cholinergic Agonist In
    Neuropsychopharmacology (2005) 30, 1076–1087 & 2005 Nature Publishing Group All rights reserved 0893-133X/05 $30.00 www.neuropsychopharmacology.org Alterations in Behavioral Responses to a Cholinergic Agonist in Post-Pubertal Rats with Neonatal Ventral Hippocampal Lesions: Relationship to Changes in Muscarinic Receptor Levels 1,2 1 1 ,1,2 Franc¸ois Laplante , Osamu Nakagawasai , Lalit K Srivastava and Re´mi Quirion* 1 2 Douglas Hospital Research Centre, Department of Psychiatry, McGill University, Montreal, Que´bec, Canada; Department of Pharmacology/ Therapeutics, McGill University, Montre´al, Que´bec, Canada Excitotoxic neonatal ventral hippocampal (NVH) lesion in rats is considered as a putative animal model of schizophrenia as lesioned animals show characteristic post-pubertal emergence of neurochemical and behavioral abnormalities analogous to some of those seen in this disease. Converging evidence points to the involvement of central cholinergic system in this neuropsychiatric disorder, and our previous studies have suggested that cholinergic neurotransmission may be altered in post-pubertal NVH lesioned rats. We investigated here muscarinic receptor reactivity in NVH lesioned animals by measuring the effects of the muscarinic receptor agonist oxotremorine on physiological responses known to be modulated by these receptors such as body temperature, salivation, tremor, pain, and prepulse inhibition of the acoustic startle (PPI). Quantitative receptor autoradiography revealed that post-pubertal NVH lesioned animals display increased levels of [3H]pirenzepine/M -like and [3H]AFDX-384/M -like receptor binding sites in the striatum, nucleus accumbens, and in 1 2 subareas of the dorsal hippocampus. Moreover, in response to the systemic administration of oxotremorine (0.25 mg/kg), post-pubertal NVH lesioned rats exhibited increases in salivation and tremor, and a greater reduction in body temperature compared to sham control animals.
    [Show full text]
  • Genetic Variants in PLCB4/PLCB1 As Susceptibility Loci for Coronary Artery
    www.nature.com/scientificreports OPEN Genetic variants in PLCB4/PLCB1 as susceptibility loci for coronary artery aneurysm formation in Received: 27 March 2015 Accepted: 04 September 2015 Kawasaki disease in Han Chinese Published: 05 October 2015 in Taiwan Ying-Ju Lin1,2, Jeng-Sheng Chang3,4, Xiang Liu5, Hsinyi Tsang5, Wen-Kuei Chien6, Jin-Hua Chen6,7, Hsin-Yang Hsieh3,8, Kai-Chung Hsueh9, Yi-Tzone Shiao10, Ju-Pi Li2,11, Cheng-Wen Lin12, Chih-Ho Lai13, Jer-Yuarn Wu2,14, Chien-Hsiun Chen2,14, Jaung-Geng Lin2, Ting-Hsu Lin1, Chiu-Chu Liao1, Shao-Mei Huang1, Yu-Ching Lan15, Tsung-Jung Ho2, Wen-Miin Liang16, Yi-Chun Yeh16, Jung-Chun Lin17 & Fuu-Jen Tsai1,2,18 Kawasaki disease (KD) is an acute, inflammatory, and self-limited vasculitis affecting infants and young children. Coronary artery aneurysm (CAA) formation is the major complication of KD and the leading cause of acquired cardiovascular disease among children. To identify susceptible loci that might predispose patients with KD to CAA formation, a genome-wide association screen was performed in a Taiwanese KD cohort. Patients with both KD and CAA had longer fever duration and delayed intravenous immunoglobulin treatment time. After adjusting for these factors, 100 susceptibility loci were identified. Four genes were identified from a single cluster of 35 using the Ingenuity Pathway Analysis (IPA) Knowledge Base. Silencing KCNQ5, PLCB1, PLCB4, and PLCL1 inhibited the effect of lipopolysaccharide-induced endothelial cell inflammation with varying degrees of proinflammatory cytokine expression. PLCB1 showed the most significant inhibition. Endothelial cell inflammation was also inhibited by using a phospholipase C (PLC) inhibitor.
    [Show full text]
  • Lamotrigine Effects Sensorimotor Gating in WAG/Rij Rats
    Published online: 2019-11-13 Original Article Lamotrigine effects sensorimotor gating in WAG/Rij rats Ipek Komsuoglu Celikyurt, Guner Ulak, Oguz Mutlu, Furuzan Yildiz Akar, Faruk Erden, Sezer Sener Komsuoglu1 Department of Pharmacology, Faculty of Medicine, Psychopharmacology Laboratory, Kocaeli University, 1Department of Neurology, Faculty of Medicine, Kocaeli University, Kocaeli,Turkey ABSTRACT Introduction: Prepulse inhibition (PPI) is a measurable form of sensorimotor gating. Disruption of PPI reflects the impairment in the neural filtering process of mental functions that are related to the transformation of an external stimuli to a response. Impairment of PPI is reported in neuropsychiatric illnesses such as schizophrenia, Huntington’s disease, Parkinson’s diseases, Tourette syndrome, obsessive compulsive disorder, and temporal lobe epilepsy with psychosis. Absence epilepsy is the most common type of primary generalized epilepsy. Lamotrigine is an antiepileptic drug that is preferred in absence epilepsy and acts by stabilizing the voltage-gated sodium channels. Aim: In this study, we have compared WAG-Rij rats (genetically absence epileptic rats) with Wistar rats, in order to clarify if there is a deficient sensorimotor gating in absence epilepsy, and have examined the effects of lamotrigine (15, 30 mg/kg, i.p.) on this phenomenon. Materials and Methods: Depletion in PPI percent value is accepted as a disruption in sensory-motor filtration function. The difference between the Wistar and WAG/Rij rats has been evaluated with the student t test and the effects of lamotrigine on the PPI percent have been evaluated by the analysis of variance (ANOVA) post-hoc Dunnett’s test. Results: The PPI percent was low in the WAG/Rij rats compared to the controls (P<0.0001, t:9,612).
    [Show full text]
  • Phencyclidine: an Update
    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • Tyrosine 140 of the γ-Aminobutyric Acid Transporter GAT-1 Plays A
    University of Montana ScholarWorks at University of Montana Biomedical and Pharmaceutical Sciences Faculty Biomedical and Pharmaceutical Sciences Publications 1997 Tyrosine 140 of the γ-Aminobutyric Acid Transporter GAT-1 Plays a Critical Role in Neurotransmitter Recognition Yona Bismuth Michael Kavanaugh University of Montana - Missoula Baruch I. Kanner Let us know how access to this document benefits ouy . Follow this and additional works at: https://scholarworks.umt.edu/biopharm_pubs Part of the Medical Sciences Commons, and the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Bismuth, Yona; Kavanaugh, Michael; and Kanner, Baruch I., "Tyrosine 140 of the γ-Aminobutyric Acid Transporter GAT-1 Plays a Critical Role in Neurotransmitter Recognition" (1997). Biomedical and Pharmaceutical Sciences Faculty Publications. 58. https://scholarworks.umt.edu/biopharm_pubs/58 This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at ScholarWorks at University of Montana. It has been accepted for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of ScholarWorks at University of Montana. For more information, please contact [email protected]. THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 272, No. 26, Issue of June 27, pp. 16096–16102, 1997 © 1997 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A. Tyrosine 140 of the g-Aminobutyric Acid Transporter GAT-1 Plays a Critical Role in Neurotransmitter Recognition* (Received for publication, February 6, 1997, and in revised form, April 8, 1997) Yona Bismuth‡, Michael P. Kavanaugh§, and Baruch I. Kanner‡¶ From the ‡Department of Biochemistry, Hadassah Medical School, the Hebrew University, Jerusalem 91120, Israel and the §Vollum Institute, Oregon Health Science University, Portland, Oregon 97201 The g-aminobutyric acid (GABA) transporter GAT-1 is tify amino acid residues of GAT-1 involved in substrate bind- located in nerve terminals and catalyzes the electro- ing.
    [Show full text]
  • Alcohol Withdrawal
    Alcohol withdrawal TERMINOLOGY CLINICAL CLARIFICATION • Alcohol withdrawal may occur after cessation or reduction of heavy and prolonged alcohol use; manifestations are characterized by autonomic hyperactivity and central nervous system excitation 1, 2 • Severe symptom manifestations (eg, seizures, delirium tremens) may develop in up to 5% of patients 3 CLASSIFICATION • Based on severity ○ Minor alcohol withdrawal syndrome 4, 5 – Manifestations occur early, within the first 48 hours after last drink or decrease in consumption 6 □ Manifestations develop about 6 hours after last drink or decrease in consumption and usually peak about 24 to 36 hours; resolution occurs in 2 to 7 days 7 if withdrawal does not progress to major alcohol withdrawal syndrome 4 – Characterized by mild autonomic hyperactivity (eg, tachycardia, hypertension, diaphoresis, hyperreflexia), mild tremor, anxiety, irritability, sleep disturbances (eg, insomnia, vivid dreams), gastrointestinal symptoms (eg, anorexia, nausea, vomiting), headache, and craving alcohol 4 ○ Major alcohol withdrawal syndrome 5, 4 – Progression and worsening of withdrawal manifestations, usually after about 24 hours from the onset of initial manifestations 4 □ Manifestations often peak around 50 hours before gradual resolution or may continue to progress to severe (complicated) withdrawal, particularly without treatment 4 – Characterized by moderate to severe autonomic hyperactivity (eg, tachycardia, hypertension, diaphoresis, hyperreflexia, fever); marked tremor; pronounced anxiety, insomnia,
    [Show full text]